Developed the fundamental technologies for peptide-based medicines. In line with proprietary technologies, company is developing sustained-release medications with a high technological entrance barrier and excellent product competitiveness, to treat life threatening and chronic diseases. Invested 2014.
Exit: January 2015: traded on Korea OTC market, July 2015: IPO on KOSDAQ at market cap of $236m.
http://www.peptron.com
Location: South Korea, Daejeon
Investors 1
| Date | Name | Website |
| - | Agate Medi... | agate-inve... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 28.11.2022 | Peptron's PT105, a sustained-release Leuprolide, established... | Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leupli... | en.prnasia... |